Similar articles

Abstract: Objectives: To measure serum and follicular resistin, steroids hormone levels in women with PCOS (polycystic ovary syndrome) (BMI (body mass index)<25 kg/m²), to assess possible correlations of resistin to hormonal and metabolic parameters and to analyze the clinical outcomes of in vitro fertilization-embryo transfer (IVF-ET) in women with PCOS and tubal infertility. Study design: We analyzed the clinical outcomes of IVF-ET in women with PCOS (BMI<25 kg/m²) and tubal infertility during the years 2002 to 2004 and compared the serum and follicular fluid resistin levels, estradiol (E₂), progesterone (P), testosterone (T) levels in 20 PCOS and 20 healthy, age-matched women without PCOS during IVF-stimulated cycles. The correlations between the resistin levels and the outcomes of IVF-ET were evaluated. Results: No significant differences in resistin levels of either serum or follicular fluid between PCOS and control group were found. However, resistin levels in serum were higher than that in follicular fluid in both groups. Multiple regression analysis showed that resistin levels in serum did not correlate with BMI, estradiol, LH (luteinizing hormone) and insulin level in fasting blood. No significant correlations were found between follicular fluid reisistin levels and fertilization rate, implantation rate, clinical pregnancy rate or early miscarriage rate in both PCOS and control groups. Conclusion: Our results show that resistin does not have correlation with the hormonal and metabolic parameters as well as the outcomes of IVF. These data suggest that resistin is unlikely to be a local determinant factor in steroidogenesis and growth and maturation of oocytes during IVF-ET in lean women with PCOS.

[1] Adams, J., Polson, D.W., Franks, S., 1986. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. (Clin. Res. Ed.), 293(6543):355-359.

[2] Burghen, G.A., Givens, J.R., Kitabchi, A.E., 1980. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab., 50(1):113-116.

[3] Chang, R.J., Nakamura, R.M., Judd, H.L., Kaplan, S.A., 1983. Insulin resistance in non-obese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab., 57(2):356-359.

[4] Dunaif, A., 1997. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr. Rev., 18(6):774-800.

[5] Fedorcsak, P., Dale, P.O., Storeng, R., Tanbo, T., Abyholm, T., 2001. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum. Reprod., 16(6):1086-1091.

[6] Fridstrom, M., Sjoblom, P., Pousette, A., Hillensjo, T., 1997. Serum FSH levels in women with polycystic ovary syndrome during ovulation induction using down-regulation and urofollitropin. Eur. J. Endocrinol., 136(5):488-492.

[7] Ghazeeri, G., Kutteh, W.H., Bryer-Ash, M., Haas, D., Ke, R.W., 2003. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril., 79(3):562-566.

[8] Hamilton-Fairley, D., Kiddy, D., Watson, H., Paterson, C., Franks, S., 1992. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br. J. Obstet. Gynaecol., 99(2):128-131.

[9] Hasegawa, I., Murakawa, H., Suzuki, M., Yamamoto, Y., Kurabayashi, T., Tanaka, K., 1999. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil. Steril., 71(2):323-327.

[10] Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R., Azziz, R., 1998. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J. Clin. Endocrinol. Metab., 83(9):3078-3082.

[11] Lobo, R.A., Gysler, M., March, C.M., Goebelsmann, U., Mishell, D.R., 1982. Clinical and laboratory predictors of clomiphene response. Fertil. Steril., 37(2):168-174.

[12] Nestler, J.E., Jakubowicz, D.J., Evans, W.S., Pasquali, R., 1998. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med., 338(26):1876-1880.

[13] Panidis, D., Koliakos, G., Kourtis, A., Farmakiotis, D., Mouslech, T., Rousso, D., 2004. Serum resistin levels in women with polycystic ovary syndrome. Fertil. Steril., 81(2):361-366.

[14] Seow, K.M., Juan, C.C., Wu, L.Y., Hsu, Y.P., Yang, W.M., Tsai, Y.L., Hwang, J.L., Ho, L.T., 2004. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum. Reprod., 19(1):48-53.

[15] Seow, K.M., Juan, C.C., Hsu, Y.P., Ho, L.T., Wang, Y.Y., Hwang, J.L., 2005. Serum and follicular resistin levels in women with polycystic ovarian syndrome during IVF-stimulated cycles. Hum. Reprod., 20(1):117-121.

[16] Shepard, M.K., Balmaceda, J.P., Leija, C.G., 1979. Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertil. Steril., 32(6):641-645.

[17] Shoupe, D., Kumar, D.D., Lobo, R.A., 1983. Insulin resistance in polycystic ovary syndrome. Am. J. Obstet. Gynecol., 147(5):588-592.

[18] Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., Lazar, M.A., 2001. The hormone resistin links obesity to diabetes. Nature, 409(6818):307-312.

[19] Urbanek, M., Du, Y., Silander, K., Collins, F.S., Steppan, C.M., Strauss, J.F., Dunaif, A., Spielman, R.S., Legro, R.S., 2003. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes., 52(1):214-217.

[20] Vandermolen, D.T., Ratts, V.S., Evans, W.S., Stovall, D.W., Kauma, S.W., Nestler, J.E., 2001. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil. Steril., 75(2):310-315.

[21] Way, J.M., Gorgun, C.Z., Tong, Q., Uysal, K.T., Brown, K.K., Harrington, W.W., Oliver, W.R., Willson, T.M., Kliewer, S.A., Hotamisligil, G.S., 2001. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem., 276(28):25651-25653.

[22] Xita, N., Georgiou, I., Tsatsoulis, A., Kourtis, A., Kukuvitis, A., Panidis, D., 2004. A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome. Fertil. Steril., 82(5):1466-1467.

[23] Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A., et al., 2001. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest., 108(7):1001-1013.